<?xml version="1.0" encoding="UTF-8"?><AQE.QER VERSION="2"><QUESTION QID="P-001068-17" AIDREF="AP-001068-17" LEG.VAL="WQ"><HEAD.Q><TI1><P.WQ>Question for written answer<NO.WQ QID="Q-P-001068-17">P-001068-17</NO.WQ></P.WQ><P.WQ>to the<DEST.WQ ORG="COM"> Commission</DEST.WQ></P.WQ></TI1><TI2><P.WQ>Rule 130</P.WQ><P.WQ><AUTHOR.WQ PERSID="125020">Paul Tang</AUTHOR.WQ><POL.GROUP GR="S&amp;D">(S&amp;D)</POL.GROUP></P.WQ></TI2><P.WQ><DATE.WQ DATE.DOC="20170216">(16 February 2017)</DATE.WQ></P.WQ></HEAD.Q><OBJ.Q OBJID="O-P-001068-17"><INT.OBJ.Q>Subject:</INT.OBJ.Q><TXT> Lack of skin-in-the-game for securitisation issuers</TXT></OBJ.Q><CONTENTS CTNID="QC-P-001068-17"><P>On 6&#xa0;February&#xa0;2017, Krahnen and Wilde from the Goethe University Frankfurt SAFE Policy Centre published a white paper on skin-in-the game in ABS transactions<NOTE TYPE="NUM"><P>J. Krahnen and C. Wilde, 2017, Skin-in-the-game in ABS transactions: a critical review of policy options, SAFE policy white paper No&#xa0;46, Goethe University Frankfurt</P></NOTE>. Their research shows that there is no or hardly any skin-in-the-game for issuers of securitisations that apply vertical and randomised selection modalities, as governed by Article&#xa0;405 of the Capital Requirements Regulation (CRR).</P><P>In view of the regulation on simple transparent and standardised securitisations, the white paper poses the following questions:</P><P>What is the Commission’s view of Krahnen and Wilde’s findings on the lack of alignment of interests for retention modalities in Article&#xa0;405(a)-(c)&#xa0;of the CRR?</P><P>Given the research, would the Commission accept that there is a need to differentiate between retention modalities in order to ensure a better alignment of interests and to make the retention modalities known to investors?</P><P>Disclosing the risk retention RM metric for transactions would provide a better representation of the skin-in-the-game of securitisation issuers. Would the Commission support such a measure?</P></CONTENTS></QUESTION></AQE.QER>